Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Long-Term Effects of High-Protein Diets on Renal Function.

Kamper AL, Strandgaard S.

Annu Rev Nutr. 2017 Aug 21;37:347-369. doi: 10.1146/annurev-nutr-071714-034426. Epub 2017 Jun 21. Review.

PMID:
28637384
2.

Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.

Sigurdsson ST, Paulson OB, Høj Nielsen A, Strandgaard S.

J Cereb Blood Flow Metab. 2014 Mar;34(3):467-71. doi: 10.1038/jcbfm.2013.219. Epub 2013 Dec 11.

3.

Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3-4--a randomized controlled study.

Boesby L, Elung-Jensen T, Strandgaard S, Kamper AL.

PLoS One. 2013 May 21;8(5):e64549. doi: 10.1371/journal.pone.0064549. Print 2013.

4.

[Secondary prevention of stroke with effective antihypertensive treatment].

Boye Knudsen S, Strandgaard S, Paulson OB.

Ugeskr Laeger. 2013 Apr 8;175(15):1024-8. Review. Danish.

PMID:
23582123
5.

Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial.

Frimodt-Møller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH.

PLoS One. 2012;7(7):e41757. doi: 10.1371/journal.pone.0041757. Epub 2012 Jul 31.

6.

Ambulatory arterial stiffness index in chronic kidney disease stage 2-5. Reproducibility and relationship with pulse wave parameters and kidney function.

Boesby L, Thijs L, Elung-Jensen T, Strandgaard S, Kamper AL.

Scand J Clin Lab Invest. 2012 Jul;72(4):304-12. doi: 10.3109/00365513.2012.682164. Epub 2012 May 6.

PMID:
22559909
7.

Low birth weight is associated with earlier onset of end-stage renal disease in Danish patients with autosomal dominant polycystic kidney disease.

Orskov B, Christensen KB, Feldt-Rasmussen B, Strandgaard S.

Kidney Int. 2012 May;81(9):919-24. doi: 10.1038/ki.2011.459. Epub 2012 Feb 1.

8.

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.

Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL.

PLoS One. 2011;6(11):e26904. doi: 10.1371/journal.pone.0026904. Epub 2011 Nov 4.

9.

Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease.

Orskov B, Sørensen VR, Feldt-Rasmussen B, Strandgaard S.

Nephrol Dial Transplant. 2012 Apr;27(4):1607-13. doi: 10.1093/ndt/gfr467. Epub 2011 Aug 26.

PMID:
21873624
10.

Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark.

Orskov B, Rømming Sørensen V, Feldt-Rasmussen B, Strandgaard S.

Clin J Am Soc Nephrol. 2010 Nov;5(11):2034-9. doi: 10.2215/CJN.01460210. Epub 2010 Jul 29.

11.

Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.

Frimodt-Møller M, Høj Nielsen A, Strandgaard S, Kamper AL.

Nephrol Dial Transplant. 2010 Mar;25(3):842-7. doi: 10.1093/ndt/gfp547. Epub 2009 Nov 9.

PMID:
19903661
12.

Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease.

Orskov B, Borresen ML, Feldt-Rasmussen B, Østergaard O, Laursen I, Strandgaard S.

Am J Nephrol. 2010;31(1):53-7. doi: 10.1159/000256657. Epub 2009 Nov 4.

PMID:
19887788
13.

Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

Oprisiu-Fournier R, Faure S, Mazouz H, Boutitie F, Serot JM, Achard JM, Godefroy O, Hanon O, Temmar M, Albu A, Strandgaard S, Wang J, Black SE, Fournier A.

Expert Rev Neurother. 2009 Sep;9(9):1289-305. doi: 10.1586/ern.09.88. Review.

PMID:
19769445
14.

[Hypertension and renal disease].

Kamper AL, Pedersen EB, Strandgaard S.

Ugeskr Laeger. 2009 Jun 15;171(25):2109-13. Danish.

PMID:
19671393
15.

[Hypertension and the brain].

Christensen H, Strandgaard S.

Ugeskr Laeger. 2009 Jun 8;171(24):2025-8. Danish.

PMID:
19523368
16.

Last Word on Point:Counterpoint: Sympathetic nervous activity does/does not influence cerebral blood flow.

Strandgaard S, Sigurdsson ST.

J Appl Physiol (1985). 2008 Oct;105(4):1375. doi: 10.1152/japplphysiol.91088.2008. No abstract available.

17.

Point:Counterpoint: Sympathetic activity does/does not influence cerebral blood flow. Counterpoint: Sympathetic nerve activity does not influence cerebral blood flow.

Strandgaard S, Sigurdsson ST.

J Appl Physiol (1985). 2008 Oct;105(4):1366-7; discussion 1367-8. doi: 10.1152/japplphysiol.90597.2008a. No abstract available.

18.

Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.

Wang D, Strandgaard S, Iversen J, Wilcox CS.

Am J Physiol Regul Integr Comp Physiol. 2009 Feb;296(2):R195-200. doi: 10.1152/ajpregu.90506.2008. Epub 2008 Aug 6.

19.

Longitudinal observations on circadian blood pressure variation in chronic kidney disease stages 3-5.

Elung-Jensen T, Strandgaard S, Kamper AL.

Nephrol Dial Transplant. 2008 Sep;23(9):2873-8. doi: 10.1093/ndt/gfn126. Epub 2008 Mar 19.

PMID:
18353888
20.

Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.

Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS.

Am J Kidney Dis. 2008 Feb;51(2):184-91. doi: 10.1053/j.ajkd.2007.09.020.

PMID:
18215696
21.

Reproducibility of pulse-wave analysis and pulse-wave velocity determination in chronic kidney disease.

Frimodt-Møller M, Nielsen AH, Kamper AL, Strandgaard S.

Nephrol Dial Transplant. 2008 Feb;23(2):594-600. Epub 2007 Nov 7.

PMID:
17989106
22.
23.

Blood pressure lowering in acute ischaemic stroke: an update on the role of angiotensin receptor blockers.

Sigurdsson ST, Strandgaard S.

J Hypertens. 2007 Apr;25(4):743-5. Review. No abstract available.

PMID:
17351363
25.

Pulse-wave morphology and pulse-wave velocity in healthy human volunteers: examination conditions.

Frimodt-Møller M, Nielsen AH, Kamper AL, Strandgaard S.

Scand J Clin Lab Invest. 2006;66(5):385-94.

PMID:
16901849
26.

Flow-associated dilatory capacity of the brachial artery is intact in early autosomal dominant polycystic kidney disease.

Clausen P, Feldt-Rasmussen B, Iversen J, Lange M, Eidemak I, Strandgaard S.

Am J Nephrol. 2006;26(4):335-9. Epub 2006 Jul 5.

PMID:
16825759
27.

[Renoprotection and blockade of the renin-angiotensin system: What shall we believe?].

Kamper AL, Feldt-Rasmussen B, Strandgaard S.

Ugeskr Laeger. 2006 Apr 10;168(15):1563. Danish. No abstract available.

PMID:
16640988
28.

Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.

Elung-Jensen T, Heisterberg J, Sonne J, Strandgaard S, Kamper AL.

Eur J Clin Pharmacol. 2005 Apr;61(2):87-96. Epub 2005 Mar 11.

PMID:
15761754
29.

The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.

Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, Levey AS; ACE Inhibition in Progressive Renal Disease (AIPRD) Study Group.

Kidney Int. 2005 Jan;67(1):265-71.

30.

The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats.

Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S.

APMIS. 2004 Jun;112(6):358-68.

PMID:
15511273
31.

The management of elevated blood pressure in acute stroke: preferential use of angiotensin II receptor antagonists?

Strandgaard S.

J Hypertens. 2004 May;22(5):877-8. Review. No abstract available.

PMID:
15097222
32.
33.

Effect of nephrectomy and captopril on autoregulation of cerebral blood flow in rats.

Pedersen TF, Paulson OB, Nielsen AH, Strandgaard S.

Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H1097-104. Epub 2003 May 15.

34.

Blood pressure response to conventional and low-dose enalapril in chronic renal failure.

Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S.

Br J Clin Pharmacol. 2003 Feb;55(2):139-46.

35.

[Microalbuminuria is associated with a fourfold increased risk of ischemic heart disease among hypertensive patients].

Jensen JS, Feldt-Rasmussen BF, Strandgaard S, Schroll M, Borch-Johnsen K.

Ugeskr Laeger. 2002 Aug 5;164(32):3773-7. Danish.

PMID:
12362612
36.

Nephrectomy and peritoneal dialysis eliminates circulating renin and controls uraemia in the rat.

Pedersen TF, Nielsen AH, Strandgaard S, Paulson OB.

J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):130-4.

PMID:
12228855
37.

High serum enalaprilat in chronic renal failure.

Elung-Jensen T, Heisterberg J, Kamper AL, Sonne J, Strandgaard S, Larsen NE.

J Renin Angiotensin Aldosterone Syst. 2001 Dec;2(4):240-5.

PMID:
11881130
38.

No effect of angiotensin II AT(2)-receptor antagonist PD 123319 on cerebral blood flow autoregulation.

Estrup TM, Paulson OB, Strandgaard S.

J Renin Angiotensin Aldosterone Syst. 2001 Sep;2(3):188-92.

PMID:
11881121
39.

[Use of angiotensin II receptor antagonists in patients with ACE inhibitor intolerance].

Karlsen FM, Strandgaard S.

Ugeskr Laeger. 2001 Aug 13;163(33):4418. Danish. No abstract available.

PMID:
11521587
40.
41.

Arterial hypertension, microalbuminuria, and risk of ischemic heart disease.

Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K.

Hypertension. 2000 Apr;35(4):898-903.

PMID:
10775558
42.

Effects of nitric oxide blockade and cyclosporin A on cardiovascular and renal function in normal man.

Hansen JM, Johansen NJ, Mollerup HM, Fogh-Andersen N, Strandgaard S.

J Hypertens. 1999 Dec;17(12 Pt 1):1707-13.

PMID:
10658936
43.

Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats.

Wang D, Iversen J, Strandgaard S.

J Vasc Res. 1999 Nov-Dec;36(6):502-9.

PMID:
10629426
44.

Urinary albumin excretion. An independent predictor of ischemic heart disease.

Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS.

Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1992-7.

PMID:
10446083
45.

[Salt restriction and blood pressure].

Strandgaard S.

Ugeskr Laeger. 1999 Apr 26;161(17):2505. Danish. No abstract available.

PMID:
10327869
46.

Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A.

Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S.

Nephron. 1998 Dec;80(4):450-7.

PMID:
9832645
47.

Urinary excretion of Tamm-Horsfall protein and epidermal growth factor in chronic nephropathy.

Torffvit O, Jørgensen PE, Kamper AL, Holstein-Rathlou NH, Leyssac PP, Poulsen SS, Strandgaard S.

Nephron. 1998;79(2):167-72.

PMID:
9647496
48.

Conflict of interest in the debate over calcium-channel antagonists.

Strandgaard S.

N Engl J Med. 1998 Jun 4;338(23):1697-8. No abstract available.

PMID:
9616065
49.

Tamm-Horsfall protein in urine after uninephrectomy/transplantation in kidney donors and their recipients.

Torffvit O, Kamper AL, Strandgaard S.

Scand J Urol Nephrol. 1997 Dec;31(6):555-9.

PMID:
9458515
50.

[Angiotensin-converting enzyme inhibition and progressing chronic nephropathy].

Kamper AL, Strandgaard S.

Ugeskr Laeger. 1997 Nov 24;159(48):7121-3. Danish. No abstract available.

PMID:
9417716

Supplemental Content

Loading ...
Support Center